Compound Tirzepatide
US$ 29.46
glp-1 receptor agonists and cardiovascular outcome trials an update Effects of on cardiometabolic outcomes in heart transplant recipients: A systematic review meta-analysis of observational studies Results of cardiovascular outcomes trials
Description
Conclusion GLP1 agonists, in particular, semaglutide and tirzepatide are remarkably effective weight loss drugs that have demonstrated a myriad of positive health benefits in obese and overweight patients, including, most notably, improved overall survival
Card Fail Rev 10:e05 Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction
Zhiwei Yan, [email protected]
Glucagon-Like Peptide-1 receptor agonists
